New study determines the ‘chilling’ future of antibiotics

Based on a new study conducted by a team of infectious disease scientists of University of Pittsburgh School of Medicine, the healthcare market was not conducive for new antibiotics targeting some of the most dangerous and drug-resistant “superbugs”.

Based on the study, the current annual sales in US for the new antibiotics to treat Carbapenem-Resistant Enterobacteriaceae (CRE) was about $101 million annually, which was s....